Refine Search

Search Results -

Terms	Documents
darbepoetin alfa	4953

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L12

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Friday, February 24, 2006 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=OR			
L12	darbepoetin alfa	4953	L12
L11	darbepoetin	4	L11
L10	L9 and l6	615	L10
L9	L8 and l7	1153	L9
L8	EPO and (glycosylation site)	6601	L8
L7	EPO and PEG	1434	L7
L6	EPO and conjugate	1845	L6
L5	L4 and (RhuEPo)	1	L5
L4	6284260.pn.	1	L4
L3	L2 and EPO	1	L3
L2	Zaharia.in.	29	L2
L1	5951996.pn.	1	L1

END OF SEARCH HISTORY

Refine Search

Search Results -

Terms	Documents
L12 and L11	4

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L13

Refine Search

Recall Text | Clear | Interrupt

Search History

DATE: Friday, February 24, 2006 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=OR			
L13	L12 and l11	4	L13
L12	darbepoetin alfa	4953	L12
L11	darbepoetin	4	L11
L10	L9 and l6	615	L10
L9	L8 and l7	1153	L9
L8	EPO and (glycosylation site)	6601	L8
L7	EPO and PEG	1434	L7
L6	EPO and conjugate	1845	L6
L5	L4 and (RhuEPo)	1	L5
L4	6284260.pn.	1	L4
L3	L2 and EPO	1	L3
L2	Zaharia.in.	29	L2
L1	5951996.pn.	1	L1

END OF SEARCH HISTORY

About Entrez
NCBI Toolbar

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorials
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

All: 10 Review: 3

Items 1 - 10 of 10 One page.

1: Craig KJ, Williams JD, Riley SG, Smith H, Owens DR, Worthing D, Cavill I, Phillips AO. Related Articles, Links

Anemia and diabetes in the absence of nephropathy.
Diabetes Care. 2005 May;28(5):1118-23.
PMID: 15855576 [PubMed - indexed for MEDLINE]

2: Biesenbach G, Schmekal B, Eichbauer-Sturm G, Janko O. Related Articles, Links

Erythropoietin requirement in patients with type 2 diabetes mellitus on maintenance hemodialysis therapy.
Wien Klin Wochenschr. 2004 Dec 30;116(24):844-8.
PMID: 15690969 [PubMed - indexed for MEDLINE]

3: Spallone V, Maiello MR, Kurukulasuriya N, Barini A, Lovecchio M, Tartaglione R, Mennuni G, Menzinger G. Related Articles, Links

Does autonomic neuropathy play a role in erythropoietin regulation in non-proteinuric Type 2 diabetic patients?
Diabet Med. 2004 Nov;21(11):1174-80.
PMID: 15498082 [PubMed - indexed for MEDLINE]

4: Stefanovic V, Antic S. Related Articles, Links

Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus.
Clin Lab. 2004;50(5-6):271-8. Review.
PMID: 15209435 [PubMed - indexed for MEDLINE]

5: Pernod G, Bosson JL, Golshayan D, Barro C, Alloatti S, Turc-Baron C, Quarello F, Jeantet A, Von Albertini B, Foret M, Lauren G, Cordonnier D, Piccoli G, Wauters JP; Diamant Alpin Collaborative Dialysis Study Group. Related Articles, Links

The Diamant Alpin Dialysis cohort study: clinico-biological characteristics and cardiovascular genetic risk profile of incident patients.
J Nephrol. 2004 Jan-Feb;17(1):66-75.
PMID: 15151261 [PubMed - indexed for MEDLINE]

6: Lin CL, Hsu PY, Yang HY, Huang CC. Related Articles, Links

Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
Ren Fail. 2003 May;25(3):445-53.
PMID: 12803508 [PubMed - indexed for MEDLINE]

7: Stefanovic V, Nesic V, Stojimirovic B. Related Articles, Links

Treatment of insulin resistance in uremia.
Int J Artif Organs. 2003 Feb;26(2):100-4. Review.
PMID: 12653342 [PubMed - indexed for MEDLINE]

8: Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, Schwartz D, Baruch R, Yachnin T, Shaked M, Schwartz I, Steinbruch S, Iaina A. Related Articles, Links

The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous

erythropoietin and intravenous iron.
Nephrol Dial Transplant. 2003 Jan;18(1):141-6.
PMID: 12480972 [PubMed - indexed for MEDLINE]

9: Ritz E. Related Articles, Links

Advances in nephrology: successes and lessons learnt from diabetes mellitus.
Nephrol Dial Transplant. 2001;16 Suppl 7:46-50. Review.
PMID: 11590257 [PubMed - indexed for MEDLINE]

10: Nowicki M, Kokot F, Kokot M, Bar A, Dulawa J. Related Articles, Links

Renal clearance of endogenous erythropoietin in patients with proteinuria.
Int Urol Nephrol. 1994;26(6):691-9.
PMID: 7759206 [PubMed - indexed for MEDLINE]

Display Summary Show 20 Sort by Send to

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

First Hit

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 6992174 B2

L11: Entry 1 of 4 File: USPT Jan 31, 2006

US-PAT-NO: 6992174
DOCUMENT-IDENTIFIER: US 6992174 B2

TITLE: Reducing the immunogenicity of fusion proteins

DATE-ISSUED: January 31, 2006

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20030166877 A1	September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gillies; Stephen D.	Carlisle	MA		US
Hamilton; Anita A.	Aberdeen			GB

US-CL-CURRENT: 530/387.3; 424/134.1, 424/141.1, 424/178.1, 424/185.1, 424/192.1, 530/350, 530/388.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc | Ima

☐ 2. Document ID: US 6969517 B2

L11: Entry 2 of 4 File: USPT Nov 29, 2005

US-PAT-NO: 6969517
DOCUMENT-IDENTIFIER: US 6969517 B2

TITLE: Recombinant tumor specific antibody and use thereof

DATE-ISSUED: November 29, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gillies; Stephen D.	Carlisle	MA		
Lo; Kin-Ming	Lexington	MA		
Qian; Susan X.	Concord	MA		

US-CL-CURRENT: 424/133.1; 424/138.1, 424/181.1, 424/182.1, 530/387.3, 530/387.7, 530/391.7

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc | Ima

☐ 3. Document ID: US 6908902 B2

L11: Entry 3 of 4 File: USPT Jun 21, 2005

US-PAT-NO: 6908902
DOCUMENT-IDENTIFIER: US 6908902 B2

TITLE: Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin

DATE-ISSUED: June 21, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Plata-Salaman; Carlos	Ambler	PA		
Smith-Swintosky; Virginia	Hatfield	PA		

US-CL-CURRENT: 514/23; 514/12, 514/451, 514/453, 514/454

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc | Ima

---

☐ 4. Document ID: US 6818613 B2

L11: Entry 4 of 4 File: USPT Nov 16, 2004

US-PAT-NO: 6818613
DOCUMENT-IDENTIFIER: US 6818613 B2

TITLE: Aqueous sustained-release formulations of proteins

DATE-ISSUED: November 16, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sharma; Basant	Bridgewater	NJ		
Jin; Renzhe	Bridgewater	NJ		
Rudolph; Sunitha	Doylestown	PA		
Cheung; Wing K.	Warren	NJ		
Begum; Selima	Edison	NJ		
Kelley; Marian	Annandale	NJ		

US-CL-CURRENT: 514/8

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc | Ima

---

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
darbepoetin	4

Display Format: CIT Change Format

ε-amino group of Lys20 to **poly(ethylene glycol)** group(s) (**PEG**), preferably to alkoxypoly(ethylene glycol) group(s), more preferably to lower methoxypoly(ethylene glycol) group(s). The muteins of this invention have the same uses as **EPO**. In particular, the muteins of this invention are useful to treat patients by stimulating the division and differentiation of committed erythroid progenitors in the bone marrow. The present invention also includes a method for the treatment of anemia in humans and the use of the muteins for the manufacturing of a pharmaceutical agent preferably for such treatment. The present invention also includes a method for preparing **erythropoietin** muteins according to the invention, which comprises the production of a **glycosylated EPO** fragment consisting of the amino acids 26-165-(**EPO** 26-165) and subsequent fusion of said fragment with a **nonglycosylated** but preferably **PEGylated EPO** fragment consisting of the amino acids 1-28 (**EPO** 1-28).

IT **510776-46-2DP**, muteins **510776-47-3DP**, muteins
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; preparation of **PEGylated** and **diglycosylated erythropoietin** with improved pharmaceutical properties in induction of erythropoiesis)
RN 510776-46-2 HCAPLUS
CN Erythropoietin (human 165-amino acid isoform) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 510776-47-3 HCAPLUS
CN Erythropoietin (human 166-amino acid isoform) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **510776-48-4**, 29-165-**erythropoietin** (human)
RL: RCT (Reactant); RACT (Reactant or reagent)
(amino acid sequence; preparation of **PEGylated** and **diglycosylated erythropoietin** with improved pharmaceutical properties in induction of erythropoiesis)
RN 510776-48-4 HCAPLUS
CN 29-165-erythropoietin (human) (9CI) (CA INDEX NAME)

EPO = Point

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **11096-26-7DP**, **Erythropoietin**, muteins
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of **PEGylated** and **diglycosylated erythropoietin** with improved pharmaceutical properties in induction of erythropoiesis)
RN 11096-26-7 HCAPLUS
CN Erythropoietin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L108 ANSWER 7 OF 27 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **2002:869575** HCAPLUS
DN **137:346941**
TI Method for improving the quality of life of patients by administration of **erythropoietin** (**RhuEPO**)
IN Zaharia, Veronica C.
PA USA
SO U.S. Pat. Appl. Publ., 4 pp., Cont.-in-part of U.S. Ser. No. 872,630.

CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002169129	A1	20021114	US 2002-133545	20020426 <--
	US 5951996	A	19990914	US 1998-18815	19980204 <--
	US 6274158	B1	20010814	US 1999-335076	19990617 <--
	US 6521245	B1	20030218	US 2001-872630	20010601 <--
PRAI	US 1998-18815	A2	19980204 <--		
	US 1998-91598P	P	19980702 <--		
	US 1999-125253P	P	19990319 <--		
	US 1999-335076	A3	19990617 <--		
	US 2001-287206P	P	20010428 <--		
	US 2001-872630	A2	20010601 <--		

AB A method for providing various benefits with the administration of different quantities of **Erythropoietin**. The method provides for enhancing the of quality of life by administration of **Erythropoietin** before a substantial increases in Hb occurs. The improvement in quality of life is independent of the hemopoietic effect. In larger quantities the administration of **RhuEPO** leads to repair of vascular damage and leads to the redistribution of the **iron** trapped in storage organs, from where it cannot be used for red blood cell production, into the hemopoietic system leading to enhanced red blood cell production

IT **11096-26-7, Erythropoietin**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for improving the quality of life of patients by administration of **erythropoietin (RhuEPO)**)
RN 11096-26-7 HCAPLUS
CN Erythropoietin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **7439-89-6, Iron**, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(method for limiting chronic blood loss by administering **RhuEPO** to prevent **iron** loss and to increase Hb level, increased mean corpuscular Hb, and increased red blood cell hemoglobinization.)
RN 7439-89-6 HCAPLUS
CN Iron (7CI, 8CI, 9CI) (CA INDEX NAME)

Fe

L108 ANSWER 8 OF 27 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:785122 HCAPLUS
DN 138:298038
TI Long-term reversal of chronic anemia using a hypoxia-regulated **erythropoietin** gene therapy
AU Binley, Katie; Askham, Zoe; Iqball, Sharifah; Spearman, Hayley; Martin, Leigh; de Alwis, Mahesh; Thrasher, Adrian J.; Ali, Robin R.; Maxwell, Patrick H.; Kingsman, Susan; Naylor, Stuart
CS Oxford BioMedica (UK) Ltd, London, OX4 4GA, UK
SO Blood (2002), 100(7), 2406-2413
CODEN: BLOOAW; ISSN: 0006-4971
PB American Society of Hematology

DT Journal
LA English
AB Anemia is a common clin. problem, and there is much interest in its role in promoting left ventricular hypertrophy through increasing cardiac workload. Normally, red blood cell production is adjusted through the regulation of **erythropoietin** (**Epo**) production by the kidney. One important cause of anemia is relative deficiency of **Epo**, which occurs in most types of renal disease. Clin., this can be corrected by supplementation with recombinant **Epo**. Here the authors describe an oxygen-regulated gene therapy approach to treating homozygous **erythropoietin**-SV40 T antigen (**Epo**-TAgh) mice with relative **erythropoietin** deficiency. The authors used vectors in which murine **Epo** expression was directed by an Oxford Biomedica hypoxia response element (OBHRE) or a constitutive cytomegalovirus (CMV) promoter. Both corrected anemia, but CMV-**Epo** -treated mice acquired fatal polycythemia. In contrast, OBHRE-**Epo** corrected the hematocrit level in anemic mice to a normal physiol. level that stabilized without resulting in polycythemia. Importantly, the OBHRE-**Epo** vector had no significant effect on the hematocrit of control mice. Homozygous **Epo**-TAgh mice display cardiac hypertrophy, a common adaptive response in patients with chronic anemia. In the OBHRE-**Epo**-treated **Epo**-TAgh mice, the authors observed a significant reversal of cardiac hypertrophy. The authors conclude that the OBHRE promoter gives rise to physiol. regulated **Epo** secretion such that the hematocrit level is corrected to healthy in anemic **Epo**-TAgh mice. This establishes that a hypoxia regulatory mechanism similar to the natural mechanism can be achieved, and it makes **EPO** gene therapy more attractive and safer in clin. settings. The authors envisage that this control system will allow regulated delivery of therapeutic gene products in other ischemic settings.
IT **7439-89-6**, **Iron**, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(long-term reversal of chronic anemia using hypoxia-regulated **erythropoietin** gene therapy)
RN 7439-89-6 HCAPLUS
CN Iron (7CI, 8CI, 9CI) (CA INDEX NAME)

Fe

IT **11096-26-7**, **Erythropoietin**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(long-term reversal of chronic anemia using hypoxia-regulated **erythropoietin** gene therapy)
RN 11096-26-7 HCAPLUS
CN Erythropoietin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1989	2	20	Lancet	
Bachmann, S	1993	41	335	J Histochem Cytochem	HCAPLUS
Bartholomew, A	2001	12	1527	Hum Gene Ther	HCAPLUS
Beall, C	2000	7	534	Gene Ther	HCAPLUS
Binley, K	1999	6	1721	Gene Ther	HCAPLUS
Boast, K	1999	10	2197	Hum Gene Ther	HCAPLUS

CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002169129	A1	20021114	US 2002-133545	20020426 <--
	US 5951996	A	19990914	US 1998-18815	19980204 <--
	US 6274158	B1	20010814	US 1999-335076	19990617 <--
	US 6521245	B1	20030218	US 2001-872630	20010601 <--
PRAI	US 1998-18815	A2	19980204 <--		
	US 1998-91598P	P	19980702 <--		
	US 1999-125253P	P	19990319 <--		
	US 1999-335076	A3	19990617 <--		
	US 2001-287206P	P	20010428 <--		
	US 2001-872630	A2	20010601 <--		

AB A method for providing various benefits with the administration of different quantities of **Erythropoietin**. The method provides for enhancing the of quality of life by administration of **Erythropoietin** before a substantial increases in Hb occurs. The improvement in quality of life is independent of the hemopoietic effect. In larger quantities the administration of **RhuEPO** leads to repair of vascular damage and leads to the redistribution of the **iron** trapped in storage organs, from where it cannot be used for red blood cell production, into the hemopoietic system leading to enhanced red blood cell production

IT **11096-26-7, Erythropoietin**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for improving the quality of life of patients by administration of **erythropoietin (RhuEPO)**)

RN 11096-26-7 HCAPLUS
CN Erythropoietin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **7439-89-6, Iron**, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(method for limiting chronic blood loss by administering **RhuEPO** to prevent **iron** loss and to increase Hb level, increased mean corpuscular Hb, and increased red blood cell hemoglobinization.)

RN 7439-89-6 HCAPLUS
CN Iron (7CI, 8CI, 9CI) (CA INDEX NAME)

Fe

L108 ANSWER 8 OF 27 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **2002:785122** HCAPLUS
DN **138:298038**
TI Long-term reversal of chronic anemia using a hypoxia-regulated **erythropoietin** gene therapy
AU Binley, Katie; Askham, Zoe; Iqball, Sharifah; Spearman, Hayley; Martin, Leigh; de Alwis, Mahesh; Thrasher, Adrian J.; Ali, Robin R.; Maxwell, Patrick H.; Kingsman, Susan; Naylor, Stuart
CS Oxford BioMedica (UK) Ltd, London, OX4 4GA, UK
SO Blood (2002), 100(7), 2406-2413
CODEN: BLOOAW; ISSN: 0006-4971
PB American Society of Hematology